To help patients with cancer learn more about how treatment may affect their quality of life, the FDA has issued draft guidance on collecting information about patient-reported outcomes in cancer clinical trials.
“Patients would like to better understand symptoms they may experience and how a cancer therapy can affect their quality of life,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence, said in a statement. “One way to accomplish this is to ask patients in clinical trials about the severity of their symptoms and ability to function using rigorously developed patient-reported outcomes.”
Kuehn BM. Collecting Patient-Reported Outcomes in Cancer Clinical Trials. JAMA. 2021;326(5):379. doi:10.1001/jama.2021.12277
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: